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INTRODUCTION 
 
 Peripheral vascular disease (PVD) is one of the significant Macro 
vascular complication of type 2 diabetes mellitus. Peripheral vascular 
disease assumes importance, for prevention of morbidity and mortality 
related to diabetic foot. PVD is the single most important factor which 
raises the incidence of leg amputation risk in type 2 DM patients. While 
peripheral neuropathy alone leads to, tropic ulcer which has an chronic 
indolent course provided super added infection is prevented and 
controlled, the presence of PVD leads to ischaemic foot which leads to 
rapid spread of infection, by means of two mechanisms.  
 
I) Due to decreased supply of oxygen, nutrients and decreased 
accessibility of neutrophils and immune effectors to the area of 
injury and infection.  
 
II) Decreased antibiotic accessibility to the affected area due to 
ischaemia.  
Further the importance of PVD assessment assumes importance 
in the light of a long duration of asymptomatic period in the 
natural course of the disease. Further the avenues for 
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development of claudication symptoms of PVD in today’s fast 
changing sedentary life style of the people are restricted, and 
hence the importance of active screening for the same with 
special emphasis on ankle – Brachial index gains   importance 
for saving the limbs of Diabetic patients.   
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REVIEW OF LITERATURE 
 
Definition: 
PVD: 
          Peripheral vascular disease is defined as signs, symptoms or abnormal 
non-invasive tests in one or both legs attributable to obstructive atherosclerotic 
disease. 
 
CLI:  
         Critical limb ischaemia is defined as chronic ischemic rest pain 
attributable to objectively proven arterial occlusive disease. 
 
PREVALENCE: 
 Several population studies have shown that diabetes is a strong risk 
factor for PVD (4). In both Diabetic and non diabetic subjects the prevalence of 
PVD increases markedly with advancing age. In several studies PVD was 
found in approximately 20% of the diabetic patients (5). In the united kingdom 
prospective diabetes study (UKPDS) PVD was found in 11% of patients after a 
follow up period of 6 years from the time of diagnosis of type 2 diabetes (6). It 
can be safely concluded based on these population studies, that PVD is a highly 
prevalent disorder, in particular in the elderly diabetic patient. Unfortunately, 
the awareness of the physicians that these patients have PVD is low, resulting 
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in inadequate preventive measures for reducing lower extremity amputation 
and to reduce the grossly elevated general cardiovascular risk (7, 8).  
 
SYMPTOMATIC AND ASYMPTOMATIC PVD: 
 Several epidemiological studies and also in the UKPDS study 
symptoms of claudication were reported in only about 25% of the patients with 
an ABI of <0.8, indicating that for each patient with claudication there are three 
patients with silent PVD(6). The reason for asymptomatic PVD could be due to 
concomitant neuropathy and many elderly patients do not walk far enough to 
experience symptoms of intermittent claudication.    
 
THE FATE OF LEG: 
               In diabetic patients the atherosclerotic changes in PVD seem to be 
more extensive and also more aggressive, resulting in faster progression of 
disease. In diabetic patients with critical limb ischemia, the risk of limb loss is 
markedly increased, gangrene being reported to develop in 40% of such 
patients (9). Diabetes is the leading cause of non traumatic lower limb 
amputation and the major reasons for a lower extremity amputation are PVD 
and / or a deep infection [8,10,11]. 
 
THE FATE OF THE PATIENT WITH PVD:  
 PVD is closely associated with occlusive disease in other arterial 
territories and it is a strong predictor of future cardiovascular morbidity and 
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mortality (9). Mortality is increased in patients with PVD in parallel to the 
severity of the disease (12). In one study approximately 20% of the patients 
with intermittent claudication and diabetes, had died after two years of follow 
up (2, 12). The poorest out come is observed in diabetic patients who have 
undergone a major amputation. 
 
SITES OF PVD: 
 The anterior tibial, posterior tibial followed next by the peroneal arteries 
are the common arteries occluded in type 2 diabetic subjects. 
 
  Involvement of deep formal artery and arteries below the knee is the 
common site of PVD in diabetic subjects with relative sparing of arteries of 
foot, rendering these distal segments suitable for byepass surgery (19,39). Why 
atherosclerosis in diabetic subjects preferably affects lower leg below knee 
arteries, is at present not well under stood. It is important to realize that foot 
vessels Dorsalis pedis, plantar and tarsal arteries are spared usually in diabetes 
subjects with PVD (2). 
 
Strandness and co workers (21) performed a blinded histological review 
of amputation specimens prepared with periodic acid schiff staining and 
demonstrated no difference between diabetic and non diabetic specimens. Both 
groups had similar patterns of atherosclerosis with a paucity of occlusive 
disease at the arteriolar level. Barner and associates (22) measured the          
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femoro-popliteal bye-pass grafts blood flow rates as a measure of vessel 
reactivity after infusion of papaverine in to the patients vascular out flow bed 
and they recorded no difference between diabetes and non diabetics. These 
studies have reinforced the newer theory that a unique small vessel disease 
does not exist in diabetic foot patients. In the past based on the false 
presumption that small vessel disease at the level of small foot arteries and 
arteriolar level, diabetics were not treated as aggressively with 
revascularization as is now standard. 
 
RISK FACTORS : 
Hyperglycemia  
 Hyperglycemia seems to be a stronger risk factor for PVD (6) .In 
UKPDS, each 1% increment in  HbA1c was associated with a 28% increase in 
the risk for PVD (6). Smoking is also a stronger risk factor for PVD (6, 23). 
Both hyperglycemia and smoking can result in the formation of advanced 
glycation end products, and in enhanced oxidative stress within the vessel wall, 
resulting in development and progression of PVD. 
 
 The Framingham offspring study examined 1554 males and 1759 
females for PVD. In this population based study the odds ratio for PVD was 2.3 
among diabetic vs non diabetic patients (13). 
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Smoking  
The Framingham heart study found a strong relationship between the 
number of cigarettes smoked and the incidence of intermittent claudication and 
a multivariate analysis identified smoking as a strong single risk factor for 
development of symptomatic obstructive arterial disease(16).The occurrence of 
intermittent claudication is twice as frequent in smokers as non smokers. In the 
EDINBURG artery study PVD prevalence strongly and positively related to 
life time cigarette smoking (17). 
 
Dyslipidaemia 
  Diabetic PVD is associated with an atherogenic dyslipidaemia, which is 
characterized by elevated triglycerides, low level of HDL cholesterol and 
increased number of small dense LDL particles and elevated LP(a) (9,5,6,24). 
 
 The association of hypercholesterolaemia with atherosclerosis of the 
lower extremities has been known for 60 years. The Edinburgh artery study 
reported a higher prevalence of PVD in association with higher serum 
cholesterol and lower HDL cholesterol in multiple logistic regression analysis 
(17).  
 
The cardiovascular health study reached similar conclusions among its 
sample of 5084 subjects aged 65 years or older with PVD defined as an, ABI 
less than 0.9 (18). 
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AGE AND MALE SEX  
  Older age is also an important risk factor for PVD in patients with 
diabetes (9, 25). As age advances there is a linear rise in risk of PVD. In the 
Edinburgh artery study the prevalence of claudication and PVD increased as 
the age advances. 
 
 Although it has been said that men are affected with symptomatic PVD 
between two to five times as frequently as women (14) in the meta analysis 
review of meijer et al a two fold or higher prevalence of claudication among 
men was seen in only one of the 13 studies (15). 
 
HYPERTENSION  
The cardio vascular health study reported about a 50% higher 
prevalence of an ABI less than 0.9 associated with hypertension in a 
multivariate analysis adjusted for age, smoking, Diabetes and 
dyslipidaemia(18). 
 
 Novel risk factors like hyperhomocystineamia have also been proposed 
to operate in development of PVD (26). 
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RELATIONSHIP OF CORONARY ARTERY DISEASE (CAD) AND 
CEREBROVASCULAR DISEASE WITH PVD: 
 Atherosclerosis, the underlying cause of PVD being a multi factorial 
progressive condition involves multiple vascular beds. Therefore it is not 
surprising that patients with PVD often have extensive CAD and cerebro 
vascular disease. The prevalence of CAD among persons with claudication in 
the general population is between two to four times higher than in non-
claudicants. Around 50% of claudicants suffer from angina, whereas patients 
with angina are six times more likely to have claudication (19). 
 
 Both claudication and asymptomatic PVD in the Edinburgh artery study 
population were significantly, associated with greater intima media thickness of 
the carotid arteries as assessed by ultrasound (20). 
 
DIABETIC NEPHROPATHY AND PVD : 
Diabetic nephropathy individuals have an increased incidence of PVD, 
and the disease has a more severe course in these patients. 
 
The diabetic nephropathy patients have an high risk of development of 
PVD since nephropathy leads to generalized acceleration of atherosclerosis in 
all regional vascular beds. 
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ABNORMAL   MICROCIRCULATION   AND   PVD:  
          Microangiopathy of tissues, and heamorrheological abnormalities play a 
lesser role in diabetic foot. Because of sensory neuropathy, a patient with 
severe ischemia may have no rest pain and because of autonomic neuropathy, 
subcutaneous A-V shunt blood flow is increased, resulting in a relatively warm 
skin, thereby falsely reassuring the clinician. Hence the importance of active 
screening for PVD becomes all the more important in type 2 diabetic subjects. 
 
DIAGNOSIS OF PVD :  
 All diabetic patients routinely should undergo clinically palpation of 
pedal pulses, dorsalis pedis and posterior tibial artery. In all diabetics over the 
age of 50 and those who have symptoms of intermittent claudication, or foot 
ulcer, should have their ankle-brachial pressure index recorded for both legs 
separately. An ABI of less than 1 is abnormal. The various investigative 
modalities for diagnosis of PVD are discussed below 
   
RECORDING OF ANKLE-BRACHIAL INDEX : 
 Ankle-brachial pressure index is recorded using a sphygmomanometer 
and hand held Doppler.  
 
            ABI = SYSTOLIC PRESSURE IN ANKLE    
                     SYSTOLIC PRESSURE IN ARM                 
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RECORDING OF TOE-PRESSURES : 
 Toe systolic pressure is measured in the hallux using a small cuff (2cm) 
and photoplethysmography or laser Doppler fluxmetry. The toe pressure is 
normally approximately 10 mmhg less than the ankle pressure. Toe arteries are 
affected by media calcification to a lesser extent. For screening purpose a toe 
systolic blood pressure index of >0.60 can be interpreted as normal. 
 
 Transcutaneous Partial Pressure of Oxygen (Tcpo2) – The tcpo2 can 
be measured with a heated oxygen sensitive probe, which is placed on the 
dorsum of foot. Several studies have shown that tcpo2 values can identify 
patients at risk for foot ulceration. Normally values are usually > 60 mmhg. 
However, it should be noted that various systemic factors such as hypoxia or 
local factors such as edema and inflammation can affect the measurement, 
resulting in falsely low values.  
 
DUPLEX SCANNING: 
 The Doppler ultrasonic flow detector with the combination of real time 
B-mode scanning in colour and Doppler spectral analysis, referred to as duplex 
scanning, is the most accurate non invasive method of detecting and following 
vascular lesions. In addition to providing an image of vascular lesions, it also 
permits an estimation of blood flow. 
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Doppler pulse velocity wave forms :  
TRIPHASIC FLOW : 
  There is a rapid forward flow component during systole, a transient flow 
reversal during early diastole and a slower forward flow component during late 
diastole. This is the normal triphasic flow.  
 
Biphasic flow : 
 Losing the forward flow component during late diastole 
   
Monophasic flow : 
  Wave form is dampened, the systolic peak is lowered and the rate of rise 
is delayed.  
 
Digital subtraction angiography (DSA)  
               The gold standard in the evaluation of diabetic patients with PVD is 
digital subtraction angiography. Here the images of conventional angiography 
have been greatly enhanced with the advent of this technique, which utilizes 
subtraction of the bone and soft tissue components to provide better 
visualization of the contrast column inside the vessels. 
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BACKGROUND AND PURPOSE OF  
THE STUDY 
 
 Although Diabetic Peripheral Neuropathy and Peripheral Vascular 
Disease (PVD) both contribute to the development of diabetic foot, the risk of 
amputation raises steeply only if there is associated PVD (2). 
 
   Once there is presence of PVD in an individual, the time duration taken 
up for development of gross limb and life threatening sepsis after an injury is 
very rapid and interventions to augment peripheral blood flow during such an 
acute active sepsis is not possible always. Hence the importance lies in 
identifying the risk factors responsible for the development of PVD in type 2 
diabetes, and in active screening for PVD in all diabetic subjects. Effective 
implementation of preventive measures in the targeted high risk group will 
pave the way for Limb protection. Moreover PVD is a sign of severe 
generalized atherosclerosis (especially CAD), which should be treated 
aggressively.  
 
            Diabetes predominately leads to PVD in the infrageniculate arteries and 
the risk factors associated with development of PVD in diabetes are found to be 
advancing age, uncontrolled hyperglycemia, hypertension, dyslipidaemia and 
smoking.  
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AIM OF THE STUDY 
 
1. To investigate the prevalence of PVD among type 2 diabetes patients.  
 
2. To assess the risk factors associated with development of PVD. 
 
3. To correlate the prevalence of cardiovascular risk factors and vascular 
complications of type 2 diabetes with abnormal ABI (ABI<1). 
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MATERIALS AND METHODS 
 
 112 randomly chosen type 2 diabetic subjects attending our Government 
Rajaji Hospital, Diabetology department OP between June 2008 to November 
2008 have formed the study sample. Patients who have other potential causes 
for PVD other than diabetes related factors were excluded from the study. The 
exclusion criteria used were  
 
1. Clinical evidence of thromboangitisobliterans. 
2. Suspected arteritis subjects. 
 3. Patients suffering from hypercoagulable states including heamotologic 
diseases. 
4. Hypothyroidism 
5. Collagen vascular disorders 
6. Valvular heart disease 
   
STUDY DESIGN: 
Cross sectional observational analytical study.  
 
Patients were interviewed with special note on elicitation of history 
regarding symptoms of PVD, in the form of intermittent claudication, 
Ischeamic rest pain, history of foot ulcers in the past and present. Smoking was 
recorded in pack-years of cigarettes smoked.  
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 Duration of diabetes since diagnosis was recorded and they were 
grouped accordingly. The anthropometric measurements were recorded and the 
body-mass index was calculated. Waist-hip ratio was also recorded. 
 
          The blood pressure was recorded in both the upper limbs and both the 
lower legs using the standard B.P cuff. Hypertension was detected if the upper 
limb BP was 140/90 or above as per JNC VII norms and also if they are already 
documented to be hypertensive or on anti-hypertensive medications. If patient 
is a known hypertensive, the duration of hyper tension since diagnosis was also 
noted.  
 
 An comprehensive physical examination was done and findings 
recorded. Special importance was given to foot examination. Peripheral 
neuropathy assessment was done using simmel-weiss monofilament testing and 
timed vibration sense perception recordings. Symptoms of peripheral 
neuropathy were also noted. 
   
METHOD OF PERIPHERAL VASCULAR DISEASE DETECTION AND 
ASSESSMENT  
RECORDING OF ANKLE-BRACHIAL INDEX (ABI) :  
The patient is placed in the supine position, a cuff, usually the same as 
used for the brachial pressure and connected to a sphygmomanometer is 
applied to the lower calf just above the ankle. The hand held Doppler probe         
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(5-8 MHz) is positioned over the posterior tibial artery and the cuff is rapidly 
inflated to a pressure sufficient to arrest blood flow. Subsequently the cuff is 
deflated slowly and the cuff pressure at which pulsatile flow returns is 
determined. Similar recording is done for dorsalis pedis artery also. The higher 
of the two recording is the ankle systolic pressure.  
 
               ABI is calculated by dividing this ankle pressure by the Doppler 
pressure measured similarly in the right brachial artery (2, 27, 6). The two 
consecutive readings were taken. The value for the worse leg was taken in to 
account. 
 
              An ABI >= 1 is normal and if it is between 1 to 0.8 indicates milder 
form of peripheral vascular disease and an ABI <0.8 to >0.6 is categorized as 
moderately severe PVD, and most of these patients will have single segment 
occlusion (9, 28, 29). ABI values below 0.6 indicate critical limb ischemia and 
usually indicate severe multi- segment disease of peripheral arteries.  
Limitations of ABI is that the diabetic patient may have media calcification of 
the arteries of the lower leg which may be less compressible and                         
incompressible arteries, thus a normal value does not exclude a diagnosis of 
PVD. An ABI >=1.15 suggests that the ankle pressure is falsely elevated (27). 
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 In spite of this limitation, still ABI remains the best screening procedure 
for PVD in diabetes subjects as proposed by the American diabetes 
association.(2, 3). 
 
 In this present study patients who had an ABI of >=1.15 were screened 
with duplex color Doppler imaging for screening for PVD, to overcome this 
limitation.  
 
Screening for Diabetic Nephropathy was done by means of screening 
for proteinuria using urine dipstick, and renal parameters of blood urea and 
serum creatinine were estimated. Urine deposits were done to exclude urinary 
tract infection as a cause of proteinuria.  Patients who were initially classified 
as diabetic nephropathy, had their diagnosis confirmed with corroboration of 
fundus opinion of Opthalmologist and renal size imaging by USG abdomen 
and pelvis.  
 
 Screening for Diabetic Retinopathy was done by subjecting all the 
study subjects for an indirect opthalmoscopy at our government rajaji hospital 
opthalmology department. Patients were categorized under three heads, viz.., 
no retinopathy, non-proliferative diabetic retinopathy and proliferative diabetic 
retinopathy using ETDRS criteria. (ETDRS - Early Treatment in Diabetic 
Retinopathy Study Criteria). 
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Screening for Coronary Artery Disease was done with details of 
previous medical records and fresh resting E.C.G. Patients who have a history 
suggestive of angina but with inconclusive resting E.C.G., had been referred to 
department of cardiology, and they were classified as per the investigations 
echocardiogram, treadmill exercise ECG and the expert opinion of the 
cardiologist. 
 
Screening for Cerebro Vascular Disease was done by examination for 
diminished unequal carotid pulse with bruite on auscultation and prior transient 
ischeamic attacks and strokes were taken in to account. 
 
      Hyperglycaemia and dyslipidaemia was assessed by estimating the FPG 
and fasting serum lipid profile of the study subjects after an 10 hours fasting. 
 
   Serum total cholesterol, HDL-cholesterol and TRIGLYCERIDES were 
directly biochemically estimated and LDL-cholesterol was calculated as per 
freedwall’s equation.   
 
20 
 
 
 
Statistical Tools  
The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2002).  
 
 Using this software, range, frequencies, percentages, means, standard 
deviations, chi square and 'p' values were calculated. Kruskul Wallis chi-square 
test was used to test the significance of difference between quantitative 
variables and Yate’s test for qualitative variables. A 'p' value less than 0.05 is 
taken to denote significant relationship. 
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RESULTS AND OBSERVATIONS OF  
THE STUDY 
 
PREVALENCE OF PERIPHERAL VASCULAR DISEASE 
 The total number of cases studied were 112. The prevalence of 
peripheral vascular Disease, as screened by Doppler ankle Brachial 
systolic pressure index was 17.9% (n = 20) (Table 7). 
 
Age Distribution of PVD 
 The age of patients studied ranged from 31 years to 80 years with a 
mean age of 58.8 years + / - 10.5 S.D. fairly depicting the age group of 
type 2 diabetic subjects. 
 
 As age advances there is a progressive rise in prevalence of 
peripheral vascular disease. As each decade of life advances, there is a 
linear and progressive rise in prevalence of peripheral vascular disease 
with maximum prevalence in the geriatric age group. (Table 10) The 
mean age of the group with PVD is 58.9 years + / - 11.3 S.D.  The 
progressive rise in prevalence of PVD with advancing age was 
statistically significant with a P value of 0.0148. 
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Sub – group analysis among PVD patients showed that as age 
progresses there was also progressive increase in severity of PVD which 
was evident by the progressive decline in ABI values with advancing age 
(P = 0.0021), (Table 13). 
 
SEX DISTRIBUTION  
Males constituted 58% ( n = 65) and females 42% (n = 47) of the 
study group (Table 2), Prevalence of PVD was 20% among the males      
(n = 13) and 14.9% among the females (n = 7) (Table - 9). But the male 
sex preponderance was not statistically significant (P = 0.6553). 
 
There was no correlation between sex and severity of progression 
of PVD, as indicated by mean ABI values comparison. (Table - 14).         
(P = 0.2495). 
 
BODY MASS INDEX (BMI) AND WAIST HIP RATIO (WHR) 
DISTRIBUTION  
 BMI and waist Hip ratio was calculated for all patients. The BMI 
ranged from 19 to 33.2 with a mean of 24.8 + / - 2.3 S.D.  The waist hip 
ratio ranged from 0.7 to 1.16 with a mean of 0.87 + / - 0.09 S.D. 
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 Sub – group analysis revealed that the sub group affected with 
PVD had statistically significant higher BMI, than non – affected subjects 
(P = 0.0221) (Table 10). Similarly the sub – group with PVD had higher 
waist hip ratio values which was also statistically significant (P = 0.0014) 
(Table 10). 
 
DURATION OF DIABETES MELLITUS AND PVD 
The duration of diabetes ranged from newly detected to 28 years, 
with a mean duration of 8.2 years + / - 6.24 S.D. For patients affected 
with PVD, the duration of diabetes was found to be longer than others. 
The mean duration of diabetes for the PVD sub group is 11.47 years + / - 
7.58 S.D. While for the rest of the study group it is 7.49 years + / - 5.72 
S.D. which was statistically significant. (P = 0.0304) (Table 10). 
 
FASTING PLASMA GLUCOSE (FPG) 
 Fasting plasma glucose was Bio- chemically analyzed for all the 
subjects. And it ranged from 88 – 290mg% with a mean FPG of 155.7 mg 
% + /-  36.9 S.D. 
 
 The control of diabetes was relatively poor among the subjects with 
PVD, when compared with the rest of the study group. The mean FPG for 
the PVD sub group is 173.6mg % + / - 34.9 SD, while for the other 
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subjects the mean FPG is 151.8 mg % + / - 36.3 SD and the difference 
was statistically significant. (P = 0.006) (Table 10). 
 
HYPERTENSION AND PVD. 
 Prevalence of hypertension was 50.9 % (n = 57) among the study 
group, which correlates with established fact.  
 
 Among the hypertensive diabetic subjects (n=57), 26.3% had 
peripheral vascular disease and the prevalence of PVD among 
normotensive diabetes subjects (n = 55) was 9.1% (P = 0.0329) 
(Table17). 
 
 Hypertension raised the risk of PVD, nearly three fold among type 
2 diabetic patients. Duration of hypertension among hypertensive diabetic 
subjects ranged from newly detected to 28 years with a mean duration of 
7.18 years + / - 6.04SD. 
 
Among the hypertensive diabetic subjects, the mean duration of 
hypertension among PVD subjects was 10.83 year + / - 7.79 SD, which 
was significantly higher than the non – PVD sub group mean of 5.87 year 
+ / - 4.75 SD (P = 0.0165) (Table 10). 
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SMOKING  
41.5% of male patients (N = 27) were smoking in the study   group. 
The duration of smoking ranged from 5 - 35 pack   years. There was no 
smoking in the female sub – set.  
 
Smokers had more than four fold increased risk of having PVD 
compared with non – smokers. 
 
ABI was less than I in 37.04% of the smokers ( n = 10) and 
whereas it was 7.89% among the non – smoking males. (n = 3), which 
was statistically significant (P = 0.0098) (Table 12). 
 
There was a positive linear correlation between the duration of 
smoking  (In pack  - years ) and risk of development of PVD (Table 15). 
 
HYPERTENSION AND SMOKING  
 Multivariate analysis showed a significant higher risk of PVD 
among smoking Hypertensive Diabetic males, compared to non smoking 
Hypertensive Diabetic males.  
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Smokers among Hypertensive Diabetic males had 58.3% 
prevalence of PVD (ABI < 1) compared to 14.3% among non – smoking 
Hypertensive Diabetic males    (Table 16) (P=0.0164). 
 
Thus Smoking is an strong additional risk factor for peripheral 
vascular disease in hypertensive individuals. 
 
 Similarly, in the PVD sub – group the mean ABI of  Normotensive 
smokers was 0.85 +/- 0.12 S.D, while  that of hypertensive smokers was 
0.58 +/- 0.15 S.D. (P=0.0304) (Table 20). 
 
 Thus, the presence of hypertension in a smoker, significantly 
increases the risk of peripheral vascular disease.  
 
 Hence, it could be inferred that the addition of smoking is an 
independent strong risk factor, both in normotensive and hypertensive 
Diabetic subjects and the risk raises significantly when smoking is 
associated with hypertension.  
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DYSLIPIDAEMIA AND PVD 
 Fasting serum lipid profile was analysed in all the subjects. The 
LDL – cholesterol ranged from 85Mg% to 164mg%  with a mean of 
124.2mg % + / - 16.2 SD. HDL cholesterol ranged from 25mg% to 
64Mg% with a mean for 33.9 % + / - 6.1 SD. Serum triglycerides ranged 
from 84mg% to 302mg% with a mean of 164.9mg %+ / - 35.8 SD. 
 
 Mean LDL – cholesterol values in the PVD – sub group was 136.1 
mg + / - 10.4 SD compared to 121.6mg% + / - 16.2SD in the non – PVD 
sub – group (P = 0.0001). HDL Cholesterol mean value in the PVD sub – 
group was 30.5 mg % + / - 4.7 SD compared to 34.7mg % + / - 6.1 SD in 
the non – PVD group. (P = 0.0009). 
 
 Similarly mean triglycerides value in the PVD sub – group was 
197.5 Mg% +/-43.7SD compared to 157.8mg% + / - 29.7 SD in the non – 
PVD group. (P = 0.0001) (Table 11)  
 
 Difference in the lipid parameters above were all statistically 
significant. This shows that individuals with a triad of increased LDL – 
cholesterol, lower HDL – cholesterol (Higher LDL / HDL ratio) and 
increased triglycerides were more at higher risk for peripheral vascular 
disease.  
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SYMPTOMATIC AND ASYMPTOMATIC PVD 
 Symptoms of PVD in the form of intermittent claudication, foot 
ulcers past and present, were present in 50% of the patients with PVD 
(ABI <1) (Table 19)  
 
 One patient presented with intermittent claudication symptoms, but 
the ABI was more than 1, the patient was referred for further 
investigations to vascular surgery department, in the form of post – 
exercise recording of ABI, duplex Doppler scanning of lower limb 
vessels, x-ray of legs for screening of extensive moncke bergs medial 
calcification of arteries.  
 
 Interesting observation to note is that patients with mild PVD (ABI 
> 0.8 to < 1), had relatively no symptoms, and as the ABI values decline, 
there was a trend towards development of symptoms. But, however, there 
were also asymptomatic patients even in the severe PVD group. 
 
 Thus, it is evident that while due importance to be given for 
symptoms of PVD, since a significant majority of patients are 
asympomatic it is imperative that all Diabetic subjects be actively 
screened for PVD with objective measurement of ABI, for identifying 
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and implementing preventive strategies for foot protection and general 
cardio vascular protection.   
 
CORONARY ARTERY DISEASE (CAD) AND PVD 
 The prevalence of CAD in the study group was 20.5% (n=23).  
Coronary artery disease was present in 60% of the patients with 
abnormally low ABI (ABI <1) (n=12) compared to 12% among patients 
with ABI in the normal range (n=11)  (Table 18).  This shows that 
patients with peripheral vascular disease, as defined by an ABI of < 1, 
significantly have higher prevalence of coronary atherosclerosis, and an 
ABI of < 1 is to be considered as an coronary artery disease equivalent; 
and ABI < I is an good marker of silent CAD, in type 2 Diabetic subjects.  
 
 More over analysis revealed 52.2%of coronary artery disease 
patients also had evidence of PVD in the form of ABI <1, compared to 
9% among non – CAD subjects.  
 
NEPHROPATHY AND PVD 
 Nephropathy was present in 7.1% of type 2 diabetes patients. 
Among the patients with nephropathy, there was a high prevalence of 
PVD to the extent of 75% (Table 18) 
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 Thus, its evident that development of Diabetic Nephropathy 
Significantly increases the risk of development of co – morbid PVD, 
since nephropathy leads to generalized acceleration of atherosclerosis in 
all the regional vascular beds.  
 
DIABETIC RETINOPATHY AND PVD 
 The prevalence of Diabetic retinopathy was 23.2% in the study 
group. Among patients with Diabetic retinopathy, 19% had proliferative 
diabetic retinopathy.  
 
 Among the patients with Diabetic retinopathy, 42.5% (N=11) had 
PVD, compared to 9% among the others. (P=0.0006 – Significant) 
(Table18) 
 
CEREBRO VASCULAR DISEASE AND PVD 
 Cerebro vascular disease was present in 6.3% of the study group. 
Among the patients with cerebro vascular disease 71.4% (n=5) had co – 
morbid PVD, compared to 14.1% prevalence of PVD among the rest. ( 
P= 0.0019) (Table 18) 
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 25% of the patients with PVD had concomitant co- morbid cerebro 
vascular disease (n=5) compared to 2.17% prevalence of cerebro vascular 
disease among the non – PVD sub set.  
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TABLES & CHARTS 
 
A. CHARACTERISTICS OF CASES STUDIED. 
 
Table 1 : Age Distribution 
 
Cases 
Age group in years 
No % 
31-40 12 10.7 
41-50 30 26.8 
51-60 37 33 
61-70 28 25 
Above 70 5 4.5 
Total 112 100 
Range 31-80 yrs 
Mean 53.8 yrs 
S.D. 10.5 yrs 
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Table 2 : Sex Distribution 
 
Cases 
Sex 
No % 
Males 65 58 
Females 47 42 
Total 112 100 
 
 
Table 3 : Other quantitative parameters 
 
Parameter Range Mean SD 
BMI 19-33.2 24.8 2.3 
WHR 0.7 – 1.16 0.87 0.09 
Duration of DM 
(in years) 1-28 8.2 6.24 
Duration of HT 
(in years) 1-28 7.18 6.04 
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Table 4 :  Fasting Plasma Glucose and Lipid Profile parameters 
 
Parameter Range in  mg% Mean SD 
F.P. Glucose 88-290 155.7 36.9 
LDL 85-164 124.2 16.2 
HDL 25-64 33.9 6.1 
TGL 84-302 164.9 35.8 
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Table 5 : Other Qualitative Parameter 
Cases 
Parameter 
No % 
Smoking among males (65) 
Smokers 27 41.5 
Non Smokers 38 58.5 
Hyper Tension 
Present 57 50.9 
Absent 55 49.1 
Symptoms of PVD 
Symptomatic 11 9.8 
Asymptomatic 101 90.2 
PVD 
Present 20 17.9 
Absent 92 82.1 
CEVD 
Present 7 6.3 
Absent 105 93.8 
CAD 
Present 23 20.5 
Absent 89 79.5 
Nephropathy 
Yes 8 7.1 
No 104 92.9 
Fundus 
Normal 86 76.8 
Abnormal 26 23.2 
Neuropathy 
Yes 86 76.8 
No 26 23.2 
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Table 6 : Severity of PVD 
 
 
Cases Severity of PVD 
 No % 
Moderate (ABI – 0.6 to  <1) 15 13.4 
Severe (ABI < 0.6) 5 4.5 
Normal (ABI >1) 92 82.1 
Total 112 100 
 
 
Table 7 : Prevalence of PVD 
 
 
Cases 
Prevalence of 
PVD 
No % 
Total cases studied 112 100 
PVD Cases 20 17.9 
 
 
 
 
37 
 
 
B : Association of Risk factors with development of PVD 
 
Table 8   : Age and PVD  
 
PVD 
Present Absent Age Group 
No % No % 
31-40 (12) 1 8.3 11 91.7 
41-50 (30) 3 10 27 90 
51 – 60 (37) 5 13.5 32 86.5 
61 – 70 (28) 9 32.1 19 67.9 
Above 70 (5) 2 40 3 60 
Mean Age 58.9 yrs 52.7 yrs 
S.D. 11.3 yrs 10.0 yrs 
‘p’ 0.0148 Significant 
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Table 9 : Sex and PVD 
PVD 
Present Absent Sex 
No % No % 
Males (65) 13 20 52 80 
Females (47) 7 14.9 40 85.1 
‘p’ 0.6553 Not Significant 
 
 
Table 10 : Relationship between other Quantitative Variables and 
PVD 
Value for Cases with PVD 
Present Absent Variable 
Mean SD Mean SD 
‘p’ 
BMI 25.33 1.67 24.64 2.37 0.0221 Significant
WHR 0.92 0.08 0.86 0.1 0.0014 Significant
Duration of DM 
(in years) 11.47 7.58 7.49 5.72 
0.0304 
Significant
Duration HT 
(in years) 10.83 7.79 5.87 4.75 
0.0165 
Significant
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Table 11 : Relationship between FPG, Dyslipidaemia and PVD. 
 
Value for Cases with PVD 
Present Absent Variable 
Mean SD Mean SD 
‘p’ 
F.P. Glucose 173.6 34.9 151.8 36.3 0.006  Significant 
LDL 136.1 10.4 121.6 16.2 0.0001 Significant 
HDL 30.5 4.7 34.7 6.1 0.0009 Significant 
TGL 197.5 43.7 157.8 29.7 0.0001 Significant 
 
 
Table 12 : Relationship between Smoking  among males (65)and PVD 
 
Cases 
With PVD Without PVD Variable 
No % No % 
‘p’ 
Smokers (27) 10 37.04 17 62.96 
Non Smokers 
(38) 3 7.89 35 92.11 
0.0098 
Significant 
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C : STRENGTH OF ASSOCIATION BETWEEN PVD AND 
OTHER VARIABLES 
 
Table 13 : Age and severity of PVD 
 
Age in years  
Severity of PVD 
 Mean S.D. 
Mild 44.8 7 
Moderate 63.7 5.1 
Severe 67 8.1 
‘p’ 0.0021 Significant 
 
Table 14 : Sex and severity of PVD 
 
Sex 
Male Female Severity of PVD 
Mean SD Mean SD 
Mild  
ABI 0.80 < 1 4 66.7 2 33.3 
Moderate 
ABI 0.6 to 0.8 5 55.6 4 44.4 
Severe 
ABI < 0.6 4 80 1 20 
ABI Mean 
S.D. 
0.67 
0.18 
0.75 
0.14 
‘p’ 0.2495 Not Significant 
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Table 15 : Relationship between pack-years of smoking and PVD. 
 
PVD 
Present Absent Pack-years of 
smoking 
Total 
No.Of. 
Patients
N % N % 
5-10 pack years 7 2 28.6% 5 71.4% 
11-15 pack years 7 2 28.6% 5 71.4% 
16-20 pack years 11 5 45.5% 6 54.5% 
> 25 pack years 2 2 100% 0 0% 
 
 
Table 16 : Association of Hypertension and Smoking with PVD 
 
PVD 
Present Absent 
 
Among patients with 
Hypertension(33) 
No. % No. % 
Smokers (12) 7 58.3 5 41.7 
Non smokers (21) 3 14.3 18 85.7 
‘p’ 0.0164 Significant 
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Table 17 : Relationship between hypertension and PVD. 
 
Cases 
With PVD Without 
PVD 
Variables 
No. % No. % 
‘p’ 
Hypertension 
Present (57) 15 26.3 42 73.7 
Absent (55) 5 9.1 50 90.9 
0.0329 
Significant
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Table 18 : Relationship between diabetic complications and PVD. 
Cases 
With PVD Without 
PVD 
Variables 
No. % No. % 
‘p’ 
CEVD 
Present (7) 5 71.4 2 28.6 
Absent (105) 15 14.1 90 85.7 
0.0019 
Significant
CAD 
Present (23) 12 52.2 11 47.8 
Absent (89) 8 9 81 91.0 
0.0001 
Significant
Nepropathy 
Present (8) 6 75 2 25 
Absent (104) 14 13.5 90 86.5 
0.0004 
Significant
Fundus 
Abnormal (26) 11 42.5 15 57.7 
Normal (86) 9 10.5 77 89.5 
0.0006 
Significant
Neuropathy 
Present (86) 18 20.9 68 79.1 
Absent (26) 2 7.7 24 92.3 
0.1524 
Not 
Significant 
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Table 19 : Symptoms of intermittent claudication and PVD. 
Cases 
With PVD Without 
PVD 
Variables 
No. % No. % 
‘p’ 
Symptoms 
Symptomatic (11) 10 90.9 1 9.1 
Asymptomatic 101) 10 9.9 91 90.1 
0.0001 
Significant
 
 
Table 20: 
  
SMOKERS 
Hypertensive smoker Normotensive smoker 
Mean ABI S.D Mean ABI S.D 
0.58 + 0.15 0.85 + 0.12 
P= 0.0304. Significant 
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DISCUSSION 
 
PREVALENCE  
 Prevalence of peripheral vascular disease in this study was 17.9% 
which was comparable to the prevalence as described in other studies. 
Meijer etal in a meta analysis has presented age and gender adjusted 
results of the prevalence of PVD ranging from 5.5% to 26.7% (5). In the 
UKPDS PVD was rare at the time of diagnosis but after 6 years of follow 
up 11% of the patients had PVD (6). Thus, it is to be noted that PVD is a 
significant complication of type 2 diabetes  
 
SYMPTOMATIC AND ASYMPTOMATIC PVD : 
 The symptoms of intermittent claudication is seen only in 50% 0f 
the patients affected with PVD in this study. It is comparable with other 
studies, where the prevalence of symptoms among PVD patients was only 
approximately 50% (2).  This may be due to  
i. Modern age sedentary life-style.  
ii. Many elderly patients not walking far enough to experience 
symptoms of intermittent claudication.  
iii. co-existing neuropathy masking pain sensation.  
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Since, many of the patients with PVD are asymptomatic it’s vital 
for active screening with ABI in all type 2 Diabetic Subjects.  
 
SEX DISTRIBUTION : 
The prevalence of PVD was 20% among males and 14.9% among 
females in the study group. Diabetes seems to repeal the protective effect 
of female gender on PVD when compared to non diabetics as seen in 
other epidemiological studies (3). The higher prevalence among males 
could be partially due to smoking.   
 
AGING AND PVD : 
As the age advances, the prevalence and risk of development of 
PVD increases and in this study, age adjusted prevalence rates, show a 
linearly progressive raising trend, and the highest prevalence was found 
among the geriatric age group. 
 
Several epidemiological studies have shown a similar raising trend, 
proportionate to the advancing age (5, 30, 31).  Thus it’s to be noted that 
aging is an unmodifiable risk factor for PVD. And elderly type 2 diabetic 
patients to be given special attention for PVD prevention and 
management.  
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WAIST HIPRATION AND BMI :  
 Waist hip ratio and BMI were higher for the PVD sub set, 
indicating that intra abdominal adiposity in general has a important role 
in cardio-vascular diseases including PVD. 
 
HYPERGLYCAEMIA AND PVD : 
As the duration of diabetes increased, the risk of PVD increased in 
the study group. The large multi centric UKPDS study also has 
categorically proved that the duration of hyperglycaemia has a definite 
role in PVD. Fasting plasma glucose was higher among the PVD subset, 
indicating relatively poor glyceamic control when compared to the rest of 
the study group. In the large multi centric UKPDS, as the HBA1C 
increased by every 1 %, there was a increase of 28% in PVD 
prevalence(6). Tight glycaemic control in general reduces peripheral 
arterial disease and risk of amputation.  
 
HYPERTENSION AND PVD 
 Hypertension associated with diabetes raised the risk of PVD, 
nearly three fold in the study subjects. Another interesting observation 
noted in the study group was that the duration of hypertension also 
significantly correlated with the risk of PVD. In the cardiovascular health 
study hypertensive patients had a 50% increased risk of PVD, in a 
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multivariate analysis adjusted for age, smoking, diabetes and 
dyslipideamia (18). 
 
SMOKING AND PVD : 
 In the study group, smokers had more than four fold increased 
risk  of  having PVD, compared to non-smokers. Thus smoking was 
found to be the single most important risk factor in comparison to 
other risk factors. A multivariate analysis by kannel, identified smoking 
as the strongest risk factor for development of PVD (16) 
 
 In this study, smoking in a diabetic hypertensive exponentially 
increased the risk of PVD. Smoking is the single most modifiable risk 
factor and hence smokers must be actively counselled for cessation of 
smoking.  
 
DYSLIPIDAEMIA AND PVD : 
 In the study group, LDL cholesterol and serum triglycerides was 
relatively higher for PVD subset and the HDL cholesterol was low. The 
cardiovascular health study and the Edinburg artery study reported higher 
prevalence of PVD in association with higher LDL, and lower HDL 
cholesterol in multiple logistic regression analysis (17, 18). 
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 Thus, it’s evident that even relatively mild increase in LDL – 
cholesterol, coupled with high serumtriglycerides and low HDL – 
cholesterol raises the risk of PVD. Hence, management of atherogenic 
dyslipidaemia is vital, and lipid levels to be maintained within optimal 
cut-off limits.  
 
CAD AND PVD : 
 Type 2 Diabetic patients are more prone to have silent CAD as well 
as PVD. Co-morbid coronary artery disease had a higher concordance 
rate (>50%) in the study group subjects affected with PVD. This indicates 
that an atherosclerotic disease in peripheral arteries should be considered 
as an indicator of generalized cardio-vascular disease and active 
secondary preventive measures to be started for prevention of further 
cardiovascular events. It is imperative to record the ABI – periodically in 
all Type 2 diabetics, since an ABI of <1 is an CAD equivalent. This 
assumes importance since many of the patients with ABI < 1 are 
asymptomatic.  
 
DIABETIC NEPHROPATHY AND PVD : 
In the present study group, PVD (ABI<1) was present in 75% of 
the diabetic nephropathy patients. Diabetic nephropathy was the single 
most important diabetic microvascular complication associated with 
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development of PVD. The development of micro albuminuria is a  marker 
of wide spread endothelial dysfunction and development of established 
diabetic nephropathy leads to more accelerated atherosclerosis, due to 
associated unfavourably altered lipid profile, hypertension and 
procoagulant state. 
 
ASSOCIATION OF PVD WITH OTHER COMPLICATIONS OF 
DIABETES  
 The prevalence of PVD was 42.5% among patients with diabetic 
retinopathy in the study group and this under scores the importance of 
screening for PVD among patients with diabetic retinopathy. Since due to 
poor visual acuity these patients are more prone for trauma to feet, while 
walking.  
 
 25% of patients with PVD had concomitant co-morbid cerebro 
vascular disease and this indicates that PVD patients also harbour 
significant generalized atherosclerosis in other vascular territories as well. 
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SUMMARY OF THE STUDY 
 
1. Prevalence of peripheral vascular Disease in the study was 17.9% 
among Type2 Diabetes patients. 
 
2. Prevalence of PVD was 20% among males and 14.9% among 
females. 
 
 
3. There was a linear progressive raise in PVD prevalence as age 
advanced, in the study group subjects. 
 
4. 50% of the patients with PVD are totally asymptomatic. 
 
5. Waist – Hip ratio and BMI were significantly higher for the PVD 
subset. 
 
6. As the duration of diabetes increased, the risk of PVD increased. 
There was relatively poor glycaemic control in the PVD sub-set. 
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7. Hypertension, when associated with Type2 Diabetes raised the risk 
of PVD nearly three fold. The duration of Hypertension also 
significantly correlated with the risk of PVD. 
 
8. Smokers had more than four fold increased risk of PVD. Smoking 
was found to be the single most important independent risk factor 
for development of PVD. 
 
9. There was relatively higher LDL – Cholesterol, low HDL-
Cholesterol, and high Serum Triglycerides in the PVD sub-set. 
 
10. Co-Morbid Coronary artery Disease was widely prevalent (about 
60%) among the PVD sub-group (ABI < 1) 
 
11. Diabetic Nephropathy patients had a significantly higher 
prevalence of PVD.  
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CONCLUSION 
 
1. Prevalence of peripheral vascular disease is about 18% in the 
present study. This has to be viewed seriously considering the huge 
type 2 diabetic population. Thus a significant proportion of type 2 
diabetic subjects are affected by PVD, and hence due importance to 
be given for screening and prevention of PVD among type 2 
diabetes patients.   
 
2. About 50% of the PVD patients are totally asymptomatic and 
hence the need for active screening with estimation of ABI is to be 
done annually for all type 2 diabetes patients. This is important for 
prevention of lower extremity amputation. 
 
3. Central obesity, Uncontrolled hyperglycemia, hypertension, 
high LDL cholesterol, high tri glycerides, low-HDL cholesterol 
and smoking are the modifiable risk factors associated with 
development of PVD. Advancing age and male gender were found 
to be the non modifiable risk factors for development of PVD.  
 
4. Concordance rate for co-morbid CAD was very high (>50%) in 
PVD patients and hence active screening for CAD in all the PVD 
patients has to be done, even if there is no CAD symptoms. 
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5. PVD has to be given due importance, and  ABI has to be estimated 
in all type 2 diabetic patients. Low ABI is associated with 
cardiovascular complications. 
 
 Thus, ABI is a good indicator of underlying complications of 
diabetes mellitus, particularly CAD.  ABI estimation is a non 
invasive cheap, bed-side, and rapid test with a high degree of validity 
and predictive power and which does not need specially trained 
persons or costly equipments. Hence, ABI estimation should be done 
for all diabetic patients annually. 
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A STUDY ON PREVALENCE AND RISK FACTORS ASSOCIATED 
WITH PVD IN TYPE 2 DIABETES 
 
CASE PROFORMA 
 
I a )  Name     b)  Age/Sex  c) 
DOB 
 
 
  d) OP No   e) Diabetology No 
 
II i) History of Present illness :-  (With special reference to PVD ) 
 
 
 ii)  Symptoms of PVD                                                   
 
 
 
 iii) Past History:- 
 
 
 iv) Smoking                                                                       PACK YEARS 
 
 
 
 
 To Bacco CHEWER / SNUFF USER 
 SUBSTANCE ABUSER 
  
 v)  Alcoholism  
  
 III) 
 a) Type of 
DIABETES 
 
 
 b) Duration of 
Diabetes  ---------  
  (Since Diagnosis) 
 
 c) GLYCEAEMIC 
STATUS 
 
 
 IV) a) Ht.----Cm ----Wt -------Kg    
BMI------- 
  
Yes No
Yes No
Cigarettes Beedi 
Yes No
Type 1  Type 2 MODY Secondary Diabetes 
< 5 years  5-10 Years >10 Years >15 years 
Fasting<140 mg >140-<170 mg >170 mg 
Normal Over Wt Obesity 
 
 b) WHR ---------  
 
  
  
 
          V a) BP               
 
 
              b) HYPERTENSION.                       
        
 
              c) Duration of Hyper 
tension  (Years) 
                                       
  
    d) Number of Drugs used for 
Hypertension            
                   Control 
 
       VI )  LIPID STATUS   
 
                       a) LDL                                                                                        b) 
HDL                   
 
               
                        
 
 
 
 
          c) TRIGLYCERIDES                                                          d)      TOTAL 
CHOLESTEROL  
 
                                     
    
            
      VII DYSLIPIDAEMIA                       
 
 
       VIII a) Peripheral Pulses         
    
                                                            
  
 
Normal Central Obesity 
 
Yes No 
<5 Years <10 Years >10 Years  
     1    2      3      3+ 
<100    
 
100-130    >130     
Men   <40    ≥40    
Women    <50     ≥50 
<150 >150 >400 <200 <240 >240 
Yes No 
Rt Lt 
DP   
PT   
                b) Physical Fitness for  ambulation                   
 
   c) Symptoms of Intermittent claudication                    
 
   d) PVD          
 
              e)  ABI                              Rt       Lt                                                   
 
              (By Doppler)                      
   
 
                              
              IX )     MACRO PROTEINUREA   
 
              a)     
 
 
                     
               X) ON ASPIRIN           
 
 
 
 XI) COMORBID 
DISEASES                       
 
 
 
 
 
 
 
            XII) a) Presence of Mechanical foot Deformities            
 
                 b) Presence of Foot Infection 
 
    c) presence of Non-infected Trophiculcer                                    
 
    d) Duration                                                                              
_________Month/year             
  
 XIII). INVESTIGATIONS 
 
 1. Urine  Albumin Deposits 
 
 2. Hb% TC, DC, ESR  
 
Yes No 
Yes No 
Yes No 
 
 
 
Urine 
Albumin 
 
Blood Urea  
Srcreatinine  
Yes No 
Yes No 
Haematologic 
Diseases 
 
Thyroid  
CAD, Cevd  
Neuropathy  
Retinopathy  
Nephropathy  
Yes No 
Yes No 
Yes No 
 3. Plasma  Glucose 
 
 4. Blood Urea 
 
 5. Serum Creatinine 
 
 6. Lipid Profile  
 
 
 
 7. E.C.G 
 
 8. Doppler Study of Lower Limb Arteries 
F         PP 
TC LDL HDL TGL VLDL 
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1 62 Male 26 0.94 Non smoker 2 No HT AS 122 nil 
2 48 Male 27 1 Non smoker Newly detected Newly detected AS 140 nil 
3 67 Female 26 0.91 Non smoker Newly detected Newly detected SYMP. 132 Yes 
4 43 Female 25 0.89 Non smoker 1 1yrs AS 140 nil 
5 41 Female 25 0.92 Non smoker Newly detected No HT AS 199 nil 
6 38 Female 24 0.84 Non smoker 2 Newly detected AS 153 nil 
7 60 Male 26 0.95 18 Newly detected Newly detected AS 88 trace
8 46 Female 25 0.96 Non smoker 2 No HT AS 246 nil 
9 54 Female 25 0.89 Non smoker Newly detected 10 AS 153 nil 
10 60 Female 26 0.97 Non smoker Newly detected Newly detected SYMP. 226 nil 
11 50 Male 24.5 0.95 15 11 11yrs AS 206 nil 
12 53 Female 26 0.86 Non smoker Newly detected No HT AS 140 nil 
13 69 Male 27 0.9 Non smoker 1 No HT AS 160 Yes 
14 53 Male 27.4 1 1Non smoker 12 No HT AS 170 nil 
15 41 Male 26 0.9 Non smoker 5 No HT AS 170 nil 
16 63 Male 23 0.8 16 10 No HT AS 185 nil 
17 44 Female 29 1.05 Non smoker 1 No HT AS 170 nil 
18 51 Male 24.5 0.92 Non smoker 11 Newly detected AS 170 trace
19 56 Male 27 0.96 Non smoker 3 No HT AS 111 nil 
20 47 Male 24.5 0.91 Non smoker 5 Newly detected AS 176 Yes 
21 47 Male 28 1.12 8 5 3months AS 212 trace
22 64 Male 20.2 0.8 16 1.5 No HT AS 216 trace
23 62 Female 27 1.12 Non smoker 20 18 AS 198 trace
24 42 Male 21.5 0.75 10 2 No HT AS 198 nil 
25 31 Female 33.2 1.12 Non smoker 3 Newly detected AS 140 nil 
26 47 Male 27 1.05 14 1.5 No HT AS 182 trace
27 43 Female 28 0.95 Non smoker 3 3yrs AS 255 nil 
28 63 Male 21.5 0.78 Non smoker 4 months No HT AS 152 nil 
29 62 Female 27 0.92 Non smoker Newly detected 3yrs AS 262 nil 
30 50 Female 19 0.72 Non smoker 7 7yrs AS 220 nil 
31 52 Female 21 0.7 Non smoker 13 Newly detected AS 186 nil 
32 46 Female 23 0.78 Non smoker 8 No HT AS 146 nil 
33 66 Male 21 0.8 35 10 1yrs SYMP. 290 nil 
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34 65 Female 26 0.82 Non smoker 1  2 yrs AS 110 nil 
35 42 Male 24 0.86 10 2 No HT AS 110 nil 
36 50 Female 30.5 1.01 Non smoker 2 2 yrs AS 168 nil 
37 42 Female 21 0.77 Non smoker 3 No HT AS 200 nil 
38 52 Male 28.5 0.96 Non smoker Newly detected Newly detected AS 152 nil 
39 42 Male 29 1.16 16 Newly detected No HT AS 205 nil 
40 36 Male 24 0.8 Non smoker 1 1yrs AS 168 nil 
41 34 Male 27 0.96 8 Newly detected No HT AS 176 nil 
42 55 Female 24 0.8 Non smoker 6months No HT AS 180 nil 
43 45 Female 23 0.8 Non smoker 3 3yrs AS 150 nil 
44 74 Female 31 0.96 Non smoker 1 1yrs AS 178 nil 
45 41 Male 26.5 0.95 16 Newly detected 7yrs AS 186 nil 
46 55 Male 22.5 0.8 Non smoker 5 Newly detected AS 182 nil 
47 45 Male 24 0.88 20 Newly detected No HT AS 196 nil 
48 32 Female 24 0.81 Non smoker Newly detected No HT AS 146 nil 
49 40 Female 24 0.85 Non smoker 2 No HT AS 146 nil 
50 42 Female 25 0.86 Non smoker 4 4 AS 115 trace
51 52 Male 24 0.88 8 10 No HT AS 149 nil 
52 56 Male 25 0.9 Non smoker 10 10 AS 156 nil 
53 52 Male 26 0.96 Non smoker 12 7 AS 167 Yes 
54 58 Female 24 0.8 Non smoker 12 No HT AS 108 trace
55 46 Male 24 0.88 Non smoker 8 6 AS 118 nil 
56 38 Male 25 0.77 Non Smoker 4 4 AS 146 nil 
57 60 Male 25 0.85 Non smoker 12 6 AS 168 trace
58 48 Male 26 0.88 Non smoker 12 10 AS 166 nil 
59 52 Male 24 0.9 Non smoker 12 No HT AS 110 nil 
60 58 Male 27 1.01 Non smoker 16 16 SYMP. 178 trace
61 54 Female 24 0.81 Non smoker 11 11 AS 128 nil 
62 58 Male 24 0.9 12 10 No HT AS 136 nil 
63 36 Male 25 0.81 Non smoker 2 No HT AS 106 nil 
64 56 Female 25 0.88 Non smoker 11 6 AS 146 nil 
65 48 Male 24 0.9 Non smoker 8 No HT AS 138 nil 
66 62 Female 26 0.78 Non smoker 14 No HT AS 96 trace
67 64 Male 24 0.81 Non smoker 20 No HT AS 168 nil 
68 62 Female 25 0.9 Non smoker 20 15 SYMP 148 Yes 
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69 56 Female 24 0.84 Non smoker 12 8 AS 116 nil 
70 52 Male 24 0.84 Non smoker 10 No HT AS 98 nil 
71 48 Male 23 0.7 Non smoker 8 No HT AS 141 nil 
72 62 Male 26 0.86 15 10 No HT AS 156 nil 
73 39 Male 26 0.86 Non smoker 4 No HT AS 106 nil 
74 74 Female 26 0.84 Non smoker 14 No HT AS 138 trace
75 68 Female 26 0.82 Non smoker 18 10 AS 136 nil 
76 68 Male 26 0.95 10 28 28 AS 158 nil 
77 59 Male 23 0.8 Non smoker 13 13 AS 106 nil 
78 72 Male 25 0.88 Non smoker 20 20 AS. 162 Yes 
79 38 Male 23 0.75 Non smoker 2 No HT AS 116 nil 
80 55 Male 26 0.9 18 15 No HT SYMP. 220 nil 
81 42 Female 22 0.75 Non smoker 6 No HT AS 126 nil 
82 36 Female 23 0.77 Non smoker 6 No HT AS 136 nil 
83 48 Female 24 0.81 Non smoker 8 8 AS 146 trace
84 46 Male 24 0.81 8 6 No HT AS 148 trace
85 50 Male 25 0.86 Non smoker 10 No HT AS 128 nil 
86 62 Female 26 0.87 Non smoker 17 12 SYMP. 168 nil 
87 52 Male 24 0.87 Non smoker 12 No HT AS 156 nil 
88 56 Male 24 0.9      Non smoker 16 6 AS 116 nil 
89 60 Male 26 0.9 Non smoker 15 15 AS 126 trace
90 58 Female 26 0.78 Non smoker 13 No HT AS 116 nil 
91 64 Male 25 0.92 20 14 14 SYMP. 168 nil 
92 62 Female 25 0.78 Non smoker 17 No HT AS 128 nil 
93 64 Male 25 0.84 Non smoker 19 10 AS 136 trace
94 72 Male 23 0.8 Non smoker 12 No HT AS 148 nil 
95 66 Male 23 0.77 Non smoker 16 16 AS 148 nil 
96 65 Male 26 0.98 20 11 11 SYMP. 168 Yes 
97 56 Female 24 0.88 Non smoker 16 No HT AS 146 nil 
98 62 Female 24 0.88 Non smoker 14 No HT AS 156 nil 
99 55 Male 25 0.86 12 12 12 AS 156 trace
100 34 Male 25 0.86 Non smoker 6 6 AS 152 nil 
101 55 Male 23 0.78 12 10 10 AS 148 nil 
102 58 Male 26 1.01 16 11 4 SYMP. 178 Yes 
103 54 Female 23 0.78 Non smoker 10 No HT AS 161 nil 
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104 70 Male 21 0.75 Non smoker 14 No HT AS 162 trace
105 59 Female 20 0.72 Non smoker 12 8 AS 158 nil 
106 66 Female 25 0.92 Non smoker 12 No HT AS 188 nil 
107 54 Female 20 0.7 Non smoker 12 No HT AS 116 trace
108 62 Male 20 0.7 Non smoker 12 10 AS 96 trace
109 65 Female 26 0.91 Non smoker 12 No HT AS 148 nil 
110 66 Female 21 0.7 Non smoker 16 12 AS 106 nil 
111 80 Male 24 0.88 26 15 15 SYMP. 128 nil 
112 60 Male 25 0.91 18 12 No HT AS 112 nil 
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1 164 35 140 120 80 120 120 1 1 1 No 19 0.8 No Yes No Normal No 
2 115 64 84 150 90 150 150 1 1 1 No 28 0.9 No No No Normal No 
3 152 43 302 220 110 140 130 0.6 0.6 0.59 Yes 60 1.3 No No yes Abnormal Yes 
4 120 39 262 150 100 140 140 0.9 0.9 0.93 Yes 20 1 No No No Normal Yes 
5 142 32 128 130 90 130 130 1 1 1 No 20 0.8 No No No Abnormal No 
6 85 38 100 150 80 150 170 1 1.1 1 No 30 1 No No No Normal Yes 
7 92 52 138 150 90 160 170 1.1 1.1 1.07 No 17 0.8 No No No Abnormal Yes 
8 87 33 180 130 80 150 150 1.2 1.2 1.15 No 18 0.7 No No No Normal Yes 
9 118 47 114 170 120 200 170 1.2 1 1 No 18 0.7 No No No Normal Yes 
10 105 51 146 150 100 160 170 1.1 1.1 1.07 No 19 0.8 No No No Normal Yes 
11 130 30 290 140 84 160 160 1.1 1.1 1.14 No 28 1.3 No Yes No Normal Yes 
12 160 30 240 132 88 142 140 1.1 1.1 1.06 No 30 0.9 No No No Normal No 
13 120 38 180 130 80 140 140 1.1 1.1 1.08 No 38 1.4 No Yes yes Normal Yes 
14 140 30 190 90 60 100 100 1.1 1.1 1.11 No 30 0.9 No Yes No Normal Yes 
15 130 30 160 120 80 130 130 1.1 1.1 1.08 No 32 0.8 No No No Normal No 
16 130 30 160 120 70 132 132 1.1 1.1 1.1 No 30 0.9 No No No Normal Yes 
17 130 36 162 140 90 148 152 1.1 1.1 1.06 No 28 0.8 No No No Normal Yes 
18 132 32 152 150 100 162 160 1.1 1.1 1.07 No 34 0.9 No No No Abnormal Yes 
19 130 28 152 140 90 154 154 1.1 1.1 1.1 No 36 0.9 No No No Normal No 
20 156 28 190 160 90 160 160 1 1 1 No 40 1.3 No No yes Abnormal Yes 
21 148 30 196 190 80 212 206 1.1 1.1 1.08 No 38 1.2  No No No Normal Yes 
22 128 28 166 140 80 156 158 1.1 1.1 1.11 No 30 0.9 YES No No Normal No 
23 126 30 152 190 80 206 204 1.1 1.1 1.07 No 30 0.9 No No No Normal Yes 
24 132 32 162 130 90 144 146 1.1 1.1 1.11 No 30 0.9 NIL No No Normal Yes 
25 136 32 158 130 100 146 146 1.1 1.1 1.12 No 28 0.9 NIL No No Normal Yes 
26 146 30 178 110 90 110 100 1 0.9 0.91 Yes 36 0.9 NIL AWMI No Normal Yes 
27 136 32 250 150 100 164 166 1.1 1.1 1.09 No 32 0.9 NIL No No Abnormal Yes 
28 128 32 150 130 80 146 146 1.1 1.1 1.11 No 28 0.8 NIL No No Normal No 
29 138 38 200 140 90 154 156 1.1 1.1 1.1 No 32 0.9 NIL IHD No Abnormal Yes 
30 108 40 220 140 86 154 154 1.1 1.1 1.1 No 28 0.8 No No No Abnormal Yes 
31 146 28 236 180 100 170 170 0.9 0.9 0.94 Yes 36 0.8 TIA No No Abnormal Yes 
32 136 46 176 140 80 156 156 1.1 1.1 1.11 No 26 0.7 NIL No NIL Normal Yes 
33 142 26 290 120 60 60 60 0.5 0.5 0.5 Yes 36 0.9 No IWMI No Abnormal Yes 
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34 100 38 148 180 80 194 196 1.1 1.1 1.08 No 26 0.7 No No No Normal No 
35 116 30 148 110 70 120 120 1.1 1.1 1.09 No 26 0.8 No No No Abnormal Yes 
36 148 30 198 180 110 186 186 1 1 1.03 No 36 0.8 No No No Normal No 
37 116 38 200 110 80 126 124 1.2 1.1 1.13 No 28 0.8 No IHD No Abnormal Yes 
38 138 28 168 130 100 146 146 1.1 1.1 1.11 No 36 0.9 No No No Normal No 
39 146 28 196 130 80 148 146 1.1 1.1 1.11 No 26 0.8 No No No Normal Yes 
40 128 30 162 140 100 156 158 1.1 1.1 1.11 No 28 0.8 No No No Normal No 
41 128 30 176 136 88 126 136 0.9 1 0.93 Yes 28 0.8 YES No No Normal No 
42 110 38 146 140 80 150 150 1.1 1.1 1.07 No 28 0.8 No No No Normal Yes 
43 116 36 156 150 106 158 158 1.1 1.1 1.05 No 29 0.8 No No No Abnormal Yes 
44 136 32 196 210 84 218 220 1 1.1 1.04 No 32 0.9 No IHD No Abnormal Yes 
45 116 32 140 120 100 120 100 1 0.8 0.83 Yes 30 0.8 YES No No Abnormal No 
46 128 30 166 160 106 170 170 1.1 1.1 1.06 No 18 0.7 No No No Normal No 
47 136 32 206 100 70 110 112 1.1 1.1 1.1 No 22 0.8 No No No Normal No 
48 106 40 146 120 80 130 130 1.1 1.1 1.08 No 18 0.6 No No No Normal No 
49 116 46 148 150 100 160 160 1.1 1.1 1.07 No 20 0.7 No No No Normal Yes 
50 112 44 162 150 100 160 162 1.1 1.1 1.07 No 22 0.6 No No No Abnormal Yes 
51 126 30 156 140 90 150 150 1.1 1.1 1.07 No 26 0.7 No No No Normal Yes 
52 128 30 146 160 100 170 172 1.1 1.1 1.06 No 28 0.8 No IHD No Normal Yes 
53 138 30 198 80 100 160 160 0.9 0.9 0.89 Yes 48 1.7 No IWMI yes Abnormal Yes 
54 112 40 140 130 80 140 140 1.1 1.1 1.08 No 28 0.8 No No No Normal Yes 
55 118 40 160 150 98 158 160 1.1 1.1 1.05 No 30 0.7 No No No Normal Yes 
56 128 36 152 150 90 158 160 1.1 1.1 1.05 No 28 0.6 No No No Normal No 
57 131 31 156 130 80 140 140 1.1 1.1 1.08 No 30 0.7 No No No Normal Yes 
58 136 30 164 150 96 160 160 1.1 1.1 1.07 No 28 0.9 No No No Abnormal Yes 
59 106 36 136 120 80 130 130 1.1 1.1 1.08 No 30 0.8 No No No Normal Yes 
60 142 28 188 160 100 100 130 0.6 0.8 0.63 Yes 36 0.8 No CAD No Normal Yes 
61 102 42 142 150 96 160 162 1.1 1.1 1.07 No 26 0.6 No No No Normal Yes 
62 108 40 160 120 80 130 130 1.1 1.1 1.08 No 22 0.7 No No No Normal Yes 
63 98 36 148 120 86 130 132 1.1 1.1 1.08 No 26 0.6 No No No Normal No 
64 96 40 156 140 94 150 152 1.1 1.1 1.07 No 30 0.7 No No No Normal Yes 
65 102 38 142 130 70 140 142 1.1 1.1 1.08 No 26 0.6 No No No Normal No 
66 106 36 136 120 60 130 130 1.1 1.1 1.08 No 28 0.7 No No No Normal Yes 
67 138 28 158 130 70 140 142 1.1 1.1 1.09 No 28 0.8 No No No Normal Yes 
68 136 28 190 160 100 140 100 0.9 0.6 0.63 Yes 55 2.3 No No yes Abnormal Yes 
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69 128 38 168 150 86 158 160 1.1 1.1 1.05 No 29 0.8 No No No Normal Yes 
70 96 28 106 126 70 138 136 1.1 1.1 1.08 No 22 0.7 No No No Normal Yes 
71 106 39 162 130 82 140 142 1.1 14 1.08 No 29 0.8 No No No Normal No 
72 142 36 160 128 78 138 140 1.1 1.1 1.08 No 30 0.8 No ASMI No Normal Yes 
73 106 30 148 110 78 122 120 1.1 1.1 1.09 No 26 0.7 No No No Normal No 
74 126 36 156 130 88 140 142 1.1 1.1 1.08 No 32 0.8 No No No Normal Yes 
75 116 26 148 160 106 176 170 1.1 1.1 10.6 No 30 0.8 No No No Abnormal Yes 
76 138 28 186 150 100 100 100 0.7 0.7 0.67 Yes 40 1.2 No IHD No Abnormal Yes 
77 116 36 166 150 80 160 162 1.1 1.1 1.07 No 30 0.8 No No No Normal Yes 
78 136 25 168 150 90 100 90 0.7 0.6 0.6 Yes 40 1.3 No IHD yes Abnormal Yes 
79 126 30 150 130 80 140 142 1.1 1.1 1.08 No 26 0.8 No No No Normal No 
80 142 38 166 140 90 100 100 0.7 0.7 0.71 Yes 32 0.9 No No No Normal Yes 
81 106 30 156 130 70 140 142 1.1 1.1 1.08 No 26 0.7 No No No Normal No 
82 116 36 146 120 86 130 128 1.1 1.1 1.07 No 27 0.8 No No No Normal Yes 
83 118 36 136 160 100 170 168 1.1 1.1 1.05 No 30 0.9 No No No Abnormal Yes 
84 96 32 138 130 86 140 140 1.1 1.1 1.08 No 32 0.8 No No No Normal Yes 
85 108 33 140 138 76 148 150 1.1 1.1 1.07 No 32 0.7 NO No No Normal Yes 
86 136 32 168 160 110 106 110 0.7 0.7 0.66 Yes 28 0.9 TIA IWMI No Normal Yes 
87 116 34 142 120 78 130 130 1.1 1.1 1.08 No 32 0.8 NO No No Normal Yes 
88 120 34 142 150 90 160 162 1.1 1.1 1.07 No 26 0.6 NO No No Normal Yes 
89 108 35 144 150 78 158 158 1.1 1.1 1.05 No 28 0.9 No No No Normal Yes 
90 98 35 146 120 70 136 132 1.1 1.1 1.1 No 28 0.9 No No No Normal Yes 
91 133 29 196 160 110 90 90 0.6 0.6 0.56 Yes 30 0.8 No ASMI No Abnormal Yes 
92 106 35 126 120 70 132 136 1.1 1.1 1.1 No 26 0.7 No No No Normal Yes 
93 116 35 128 140 76 148 150 1.1 1.1 1.06 No 26 0.8 No IHD No Normal Yes 
94 108 36 128 130 80 140 142 1.1 1.1 1.08 No 26 0.9 No No No Normal Yes 
95 108 38 132 160 110 170 174 1.1 1.1 1.06 No 30 0.9 No IHD No Normal Yes 
96 142 26 210 160 100 100 100 0.6 0.6 0.63 Yes 48 1.8 No IWMI yes Abnormal Yes 
97 116 38 160 130 80 140 142 1.1 1.1 1.08 No 30 1 No No No Normal Yes 
98 126 38 161 120 70 132 130 1.1 1.1 1.08 No 30 0.9 No No No Normal Yes 
99 130 38 162 140 88 148 148 1.1 1.1 1.06 No 30 1.1 No No No Normal Yes 
100 136 32 166 160 80 170 174 1.1 1.1 1.06 No 32 1 No No No Normal No 
101 136 32 142 140 88 148 152 1.1 1.1 1.06 No 32 1.2 No No No Normal Yes 
102 152 26 186 190 110 100 90 0.5 0.5 0.47 Yes 56 2.8 NO IHD yes Abnormal Yes 
103 142 26 172 120 70 130 132 1.1 1.1 1.08 No 32 1 NO No No Normal No 
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104 136 28 182 140 80 150 150 1.1 1.1 1.07 No 32 1.2 TIA No No Normal Yes 
105 136 32 136 160 106 172 174 1.1 1.1 1.08 No 30 0.9 No No No Abnormal Yes 
106 132 28 190 140 90 120 100 0.9 0.7 0.71 Yes 36 0.8 No CAD No Normal Yes 
107 126 28 140 130 80 142 142 1.1 1.1 10.9 No 30 0.9 No No No Normal Yes 
108 116 32 136 130 98 144 144 1.1 1.1 1.11 No 30 0.9 No No No Normal Yes 
109 128 32 180 130 90 100 100 0.8 0.8 0.77 Yes 31 0.9 No CAD No Normal Yes 
110 116 26 126 140 100 150 154 1.1 1.1 1.07 No 30 1.2 No No No Normal Yes 
111 116 31 140 160 100 60 60 0.4 0.4 0.38 Yes 29 1.2 TIA No No Normal Yes 
112 120 38 130 130 70 142 144 1.1 1.1 1.09 No 26 0.8 NO No No Normal Yes 
 
